V-Go®
Diabetes (Insulin Delivery)
Key Facts
About MannKind Corp
MannKind Corporation has evolved from a development-stage enterprise into a multi-product biopharmaceutical company with a core mission of transforming chronic disease management through innovative, patient-centric inhaled solutions. Its competitive moat is anchored in the proprietary Technosphere® drug delivery platform, which has enabled the commercialization of Afrezza® and underpins a diversified portfolio and partnership strategy. The company is now demonstrating strong commercial execution, with FY2025 revenues reaching $349 million, driven by growth in its core products and strategic acquisitions like scPharmaceuticals.
View full company profileTherapeutic Areas
Other Diabetes (Insulin Delivery) Drugs
| Drug | Company | Phase |
|---|---|---|
| PANDA System | SFC Fluidics | Pre-clinical |